本研究旨在探讨不同分子量铁皮石斛叶多糖缓解糖脂代谢异常的可能机制,T2D小鼠的器官功能障碍和肠道菌群失调。用超滤膜从铁皮石斛叶多糖LDOP-A和LDOP-B中分离出两个部分。这里,我们提供的数据支持口服LDOP-A和LDOP-B改善高血糖症,抑制胰岛素抵抗,降低脂质浓度,改善β细胞功能。较低分子量的LDOP-A对糖尿病的疗效优于LDOP-B,同时结肠短链脂肪酸(SCFA)水平增加,即丁酸盐,Firmicutes与拟杆菌门的比例降低,增加了肠道有益细菌的丰度,乳酸菌,双歧杆菌和Akkermansia。这些结果表明,LDOP-A比LDOP-B在改善T2D方面具有更强的作用,这可能与肠道菌群微观结构变化产生的SCFA水平明显改善有关。
The present study aimed to explore the possible mechanisms underlying Dendrobium officinale leaf polysaccharides of different molecular weight to alleviate glycolipid metabolic abnormalities, organ dysfunction and gut microbiota dysbiosis of T2D mice. An ultrafiltration membrane was employed to separate two fractions from Dendrobium officinale leaf polysaccharide named LDOP-A and LDOP-B. Here, we present data supporting that oral administration of LDOP-A and LDOP-B ameliorated hyperglycemia, inhibited insulin resistance, reduced lipid concentration, improved β-cell function. LDOP-A with lower molecular weight exhibited improved effect on diabetes than LDOP-B, concurrent with increased levels of colonic short-chain fatty acids (SCFAs) i.e., butyrate, decreased ratio of Firmicutes to Bacteroidetes phyla, and increased abundance of the gut beneficial bacteria i.e., Lactobacillus, Bifidobacterium and Akkermansia. These results suggest that LDOP-A possesses a stronger effect in ameliorating T2D than LDOP-B which may be related to the distinct improved SCFAs levels produced by the change of intestinal flora microstructure.